Search Results - Bridgewater, John A.

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial by Ford, Hugo, Marshall, Andrea, Bridgewater, John A., Janowitz, Tobias, Coxon, Fareeda, Wadsley, Jonathan, Mansoor, Wasat, Fyfe, David, Madhusudan, Srinivasan, Middleton, Gary, Swinson, Daniel, Falk, Stephen, Chau, Ian, Cunningham, David, Kareclas, Paula, Cook, Natalie, Blazeby, Jane M., Dunn, Janet A.

Get full text

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial by Valle, Juan W., Wasan, Harpreet, Lopes, Andre, Backen, Alison C., Palmer, Daniel H., Morris, Karen, Duggan, Marian, Cunningham, David, Anthoney, D. Alan, Corrie, Pippa, Srinivasan, Narayanan, Maraveyas, Anthony, Ross, Paul J., Waters, Justin S., Steward, Will P., Rees, Charlotte, Beare, Sandy, Dive, Caroline, Bridgewater, John A.

Get full text

Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial by Backen, Alison C., Lopes, Andre, Wasan, Harpreet, Palmer, Daniel H., Duggan, Marian, Cunningham, David, Anthoney, Alan, Corrie, Pippa G., Madhusudan, Srinivasan, Maraveyas, Anthony, Ross, Paul J., Waters, Justin S., Steward, William P., Rees, Charlotte, McNamara, Mairéad G., Beare, Sandy, Bridgewater, John A., Dive, Caroline, Valle, Juan W.

Get full text